At Cambridge Epigenetix we believe that methylation matters to human health. So we’re developing best in class technology and services to make studying DNA methylation as easy as studying DNA sequence.
Our starting point is TrueMethyl™ oxidative bisulfite sequencing (oxBS-Seq), a novel technology that pioneers quantitative, single-base resolution sequencing of the modified bases hydroxymethyl cytosine (5hmC) and methylcytosine (5mC). TrueMethyl enables analysis of the DNA methylome with unprecedented accuracy and opens new avenues for basic research, pharmaceutical discovery and diagnostics.
Recent studies have shown that at some sites in the genome the level of 5hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. However, traditional bisulfite sequencing cannot discriminate between 5hmC and 5mC.
Co-invented by Prof. Shankar Balasubramanian, who previously co-invented the Solexa / Illumina sequencing-by-synthesis platform, and Michael Booth, innovative oxBS-Seq technology utilises a selective chemical oxidation that accurately distinguishes between 5-mC and 5-hmC.
Our technology can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays. Employing chemical oxidation gives very high conversion efficiencies and minimises sequence context effects, giving results of unparalleled quality.